Immunogenicity of recombinant human proteins: causes and consequences, Journal of Neurology, vol.251, issue.S2, pp.4-9, 2004. ,
DOI : 10.1007/s00415-004-1202-9
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Whitham RH, and the Multiple Sclerosis Collaborative Research Group (MSCRG), pp.285-294, 1996. ,
DOI : 10.1002/ana.410390304
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis, Neurology, vol.50, issue.5, pp.501266-1272, 1998. ,
DOI : 10.1212/WNL.50.5.1266
Intramuscular interferon beta-1a therapy initiated falling on a first demyelinating event in multiple sclerosis. CHAMPS Study Group, N Engl J Med, issue.13, pp.343898-904, 2000. ,
A randomized, doubleblind , dose-comparison study of weekly interferon beta-1a in relapsing MS, Neurology, issue.10, pp.591507-1517, 2002. ,
Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial, Neurology, issue.10, pp.591496-1506, 2002. ,
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis, The Lancet, vol.362, issue.9391, pp.3621184-1191, 2003. ,
DOI : 10.1016/S0140-6736(03)14541-2
Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis, Neurology, issue.11, pp.622031-2037, 2004. ,
Randomized study of once-weekly interferon ??-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study, Multiple Sclerosis Journal, vol.359, issue.1, pp.41-45, 2005. ,
DOI : 10.1016/S0140-6736(00)04725-5
Interferon ??-1b-neutralizing antibodies 5 years after clinically isolated syndrome, Neurology, vol.77, issue.9, pp.77835-843, 2011. ,
DOI : 10.1212/WNL.0b013e31822c90d7
URL : http://hdl.handle.net/2078.1/124900
Deisenhammer F: Persistency of neutralizing antibodies depends on titer and interferon-beta preparation, Mult Scler, vol.2012, issue.185, pp.610-615 ,
Neutralizing Antibodies Are Associated with a Reduction of Interferon-^|^beta; Efficacy during the Treatment of Japanese Multiple Sclerosis Patients, The Tohoku Journal of Experimental Medicine, vol.228, issue.2, pp.85-92 ,
DOI : 10.1620/tjem.228.85
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy, Neurology, vol.65, issue.1, pp.33-39, 2005. ,
DOI : 10.1212/01.WNL.0000166049.51502.6A
Anti-cytokine autoantibodies: Epiphenomenon or critical modulators of cytokine action, Biotherapy, vol.347, issue.suppl. 1, pp.39-48, 1997. ,
DOI : 10.1007/BF02678216
Interferon ??-1a in MS: Results following development of neutralizing antibodies in PRISMS, Neurology, vol.65, issue.1, pp.48-55, 2005. ,
DOI : 10.1212/01.wnl.0000171748.48188.5b
Neutralizing antibodies and efficacy of interferon ??-1a: A 4-year controlled study, Neurology, vol.65, issue.1, pp.40-47, 2005. ,
DOI : 10.1212/01.wnl.0000171747.59767.5c
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis, The Lancet Neurology, vol.9, issue.7, pp.740-750, 2010. ,
DOI : 10.1016/S1474-4422(10)70103-4
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters, Multiple Sclerosis, vol.8, issue.6, pp.523-526, 2002. ,
DOI : 10.1191/1352458502ms839oa
Physiopathologie et traitement de la fatigue dans la scl??rose en plaques, Revue Neurologique, vol.162, issue.3, pp.311-320, 2006. ,
DOI : 10.1016/S0035-3787(06)75017-2
Editorial, Multiple Sclerosis Journal, vol.48, issue.4, pp.367-368, 2006. ,
DOI : 10.1001/archneur.61.2.201
ABSTRACT:, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, vol.33, issue.01, pp.9-14, 1994. ,
DOI : 10.1016/0304-3959(85)90078-8
Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.1, pp.34-39, 2006. ,
DOI : 10.1136/jnnp.2005.065805
Cytokine mRNA expression in patients with multiple sclerosis and fatigue, Multiple Sclerosis, vol.10, issue.2, pp.165-169, 2004. ,
DOI : 10.1191/1352458504ms991oa
Fatigue in multiple sclerosis is related to disability, depression and quality of life, Journal of the Neurological Sciences, vol.243, issue.1-2, pp.39-45, 2006. ,
DOI : 10.1016/j.jns.2005.11.025
Physical dimension of fatigue correlated with disability change over time in patients with multiple sclerosis, Journal of Neurology, vol.63, issue.5, pp.633-636, 2008. ,
DOI : 10.1007/s00415-008-0761-6
Diagnostic criteria for multiple sclerosis: 2005 revisions to the ???McDonald Criteria???, Annals of Neurology, vol.6, issue.6, pp.58840-846, 2005. ,
DOI : 10.1002/ana.20703
Symptoms and signs. In McAlpine' s Multiple Sclerosis, pp.61-63, 1991. ,
PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS, Annals of the New York Academy of Sciences, vol.43, issue.6, pp.552-568, 1965. ,
DOI : 10.1111/j.1749-6632.1965.tb20235.x
Validity of a French version of the fatigue impact scale in multiple sclerosis, Multiple Sclerosis Journal, vol.8, issue.1, pp.1026-1032, 2007. ,
DOI : 10.1191/1352458505ms1148oa
Patient satisfaction with an injection device for multiple sclerosis treatment, Acta Neurologica Scandinavica, vol.24, issue.3, pp.156-162, 2006. ,
DOI : 10.1016/S0149-2918(02)85131-1
A new depression scale designed to be sensitive to change, The British Journal of Psychiatry, vol.134, issue.4, pp.382-389, 1979. ,
DOI : 10.1192/bjp.134.4.382
Étude Princeps de Validation Française de la MADRS ,
Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN?? in multiple sclerosis patients, Journal of Immunological Methods, vol.336, issue.2, pp.113-118, 2008. ,
DOI : 10.1016/j.jim.2008.03.014
The Neutralization of Interferons by Antibody. I. Quantitative and Theoretical Analyses of the Neutralization Reaction in Different Bioassay Systems, Journal of Interferon & Cytokine Research, vol.21, issue.9, pp.729-742, 2001. ,
DOI : 10.1089/107999001753124462
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis, Acta Neurologica Scandinavica, vol.273, issue.5, pp.283-287, 2006. ,
DOI : 10.1111/j.1600-0404.2006.00585.x
Gender effects on intramuscular interferon beta-1a in relapsing???remitting multiple sclerosis: analysis of 1406 patients, Multiple Sclerosis Journal, vol.11, issue.3, pp.353-360, 2011. ,
DOI : 10.1001/jama.1992.03480010072027
Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment, Multiple Sclerosis, vol.14, issue.2, pp.274-277, 2008. ,
DOI : 10.1177/1352458507082480
Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients, Neurological Sciences, vol.249, issue.S2, pp.29-227, 2008. ,
DOI : 10.1007/s10072-008-0945-y
Origin of Fatigue in Multiple Sclerosis: Review of the Literature, Neurorehabilitation and Neural Repair, vol.22, issue.1, pp.91-100, 2008. ,
DOI : 10.1177/1545968306298934
The effect of exercise therapy on fatigue in multiple sclerosis, Multiple Sclerosis Journal, vol.17, issue.9, pp.1041-1054, 2011. ,
DOI : 10.1177/1352458511401120